To include your compound in the COVID-19 Resource Center, submit it here.

Medimetriks reports Phase II data for MM36 in atopic dermatitis

In September, Medimetriks Pharmaceuticals Inc. (Fairfield, N.J.) reported data from the Phase II MUSE trial in 32 patients with atopic dermatitis showing that twice-daily topical

Read the full 255 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE